An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. (Q53149038)
Jump to navigation
Jump to search
scientific article published on 29 July 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. |
scientific article published on 29 July 2011 |
Statements
An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. (English)
Pierre I Karakiewicz
Christian U Blank
Viktor Grünwald
Sevil E Bavbek
Kurt Miller
Jean-Pascal Machiels
Se-Hoon Lee
James Larkin
Petri Bono
Sun Young Rha
Daniel Castellano
Jennifer J Knox
Robert Hawkins
Oezlem Anak
Marianne Rosamilia
Jocelyn Booth
Nicoletta Pirotta
István Bodrogi
REACT Study Group
29 July 2011
48
3
324-332